SecBot SecBot

AMRN

AMARIN CORP PLC
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0000897448 Biotech & Drug Discovery
$12.09 +0.30 (+2.54%)
Oct 26 4:00 PM ET · prev $11.79
Market cap
$249.0M
Micro cap
Median target
$12.50
+3% · range $12.00–13.00
Next earnings
Oct 27
today · EPS est. −$0.02
1 year
−36.2%
from $18.94 · Oct 28
30 days
−8.8%
from $13.25
52-week range
$11.32–18.94
−36% from high · low Oct 16
Avg volume 20D
66.4K
shares / day
Short interest
532.7K
≈2.5% of shares · +0.8%
Days to cover
7.3
at average volume
Insider net
$0
no open-market trades · since Jan 31
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest MIXED Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jan 31. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 2 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.005 → −$0.020 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.8% to 532.7K shares. 7.3 days to cover, ≈2.5% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCTRIM115,808$1.8M
RENAISSANCE TECHNOLOGIES LLCDOUBLED48,369$771.0K
BlackRock, Inc.TRIM858$13.7K
JONES FINANCIAL COMPANIES LLLPDOUBLED493$7.8K
GROUP ONE TRADING LLCDOUBLED130$2.1K
MILLENNIUM MANAGEMENT LLCADD300,536$4.3M
Point72 Asset Management, L.P.DOUBLED240,761$3.5M
BNP PARIBAS FINANCIAL MARKETSTRIM75,503$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2025
12-month targets · 2 analysts

Price is inside the target range. Median implies +3%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Jun 25, 2025Goldman Sachs
MAINTAIN
MAINTAINSell
Apr 17, 2025Goldman Sachs
MAINTAIN
MAINTAINSell
Jun 20, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jun 18, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Oct 25, 2023Jefferies
DOWNGRADE
DOWNGRADEHold
Jul 20, 2023Goldman Sachs
MAINTAIN
MAINTAINSell

Insider ledger

Form 4
$0
open-market buys or sells · since Jan 31
DateInsiderTypeValue
Aug 1, 2026
Fishman Peter L.
SVP, CFO
EXERCISE313 sh
Aug 1, 2026
Fishman Peter L.
SVP, CFO
TAX W/H$2.2K
Aug 1, 2026
Fishman Peter L.
SVP, CFO
AWARD313 sh
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
AWARD3,688 sh
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
TAX W/H$20.1K
Jul 1, 2026
Ketchum Steven B
EVP, Chief Scientific Officer
AWARD3,688 sh
Jul 1, 2026
Ketchum Steven B
EVP, Chief Scientific Officer
TAX W/H$30.1K
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
EXERCISE3,688 sh

Earnings setup

Estimates
Oct 27
reports today
−$0.02
EPS estimate, this quarter
−300%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.02-$0.02–-$0.02—$43.7M
Next Q-$0.01-$0.01–-$0.01—$46.8M
Current FY-$0.07-$0.07–-$0.07-133.3%$177.4M
Next FY-$0.06-$0.06–-$0.06-200.0%$176.8M

Short side

FINRA· Oct 15, 2026
532,662
shares short
+0.8%
vs prior settlement
7.3
days to cover
≈2.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Earnings calendar
AMRN Q3 2026 Earnings Scheduled — 2026-10-27
Oct 25, 2026 Press
Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver…
Impact 6/10
Aug 28, 2026 Press
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on…
Impact 4/10
Aug 1, 2026 Insider
Fishman Peter L. acquired via exercise 313 shares
SVP, CFO
Aug 1, 2026 Insider
Fishman Peter L. surrendered for taxes 155 shares
SVP, CFO @ $14.26 ($2.2K)
Aug 1, 2026 Insider
Fishman Peter L. was granted 313 shares
SVP, CFO
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
115,808 shares ($1.8M)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
48,369 shares ($771.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Earnings date
AMRN Q3 2026 Earnings Scheduled — 2026-10-27
Oct 25, 2026
FDA
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint…
Sep 15, 2026
Short interest
Short Interest: AMRN up 3% to 0.5M shares
Settlement 2026-09-15 | Days to cover: 10.10 | ≈2.49% of shares outstanding (est.)
Aug 31, 2026
Press release
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of…
Aug 28, 2026
FDA
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy…

SecBot reports

3 filings · 3 press releases · 0 bullish · 2 bearish · 1 neutral
All AMRN filing & press-release reports (6)